Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

DEA, 18 GOP State Attorneys General Want Public Hearing On Cannabis Rescheduling As Deadline Looms

Published 21/06/2024, 16:50
© Reuters.  DEA, 18 GOP State Attorneys General Want Public Hearing On Cannabis Rescheduling As Deadline Looms

Benzinga - by Maureen Meehan, Benzinga Editor.

In a recent federal filing, six former Drug Enforcement Administration (DEA) chiefs have called on the agency to hold a public hearing regarding President Joe Biden's mid-May proposal to reschedule marijuana from Schedule I to Schedule III.

Their logic? "Given the magnitude of the impact of the proposed rule and considering we face an unprecedented drug overdose crisis in this country, we write to emphasize that a hearing on this rulemaking is in the public interest."

If you're wondering how the opioid crisis would negatively affect rescheduling cannabis or vice versa, go to the head of the class.

In support of the DEA's request, reports Marijuana Moment,18 state attorneys general also want a hearing, presumably for the same reason.

Led by South Carolina Attorney General Alan Wilson (R) along with attorneys general from Alabama, Arkansas, Idaho, Indiana, Iowa, Kansas, Louisiana, Mississippi, Montana, Nebraska, New Hampshire, North Dakota, Oklahoma, South Dakota, Texas and Wyoming have all signed onto this request, noting that a public hearing is in "the public interest, and therefore in the interest of our states." In case you're wondering, all of the aforementioned attorney generals are in red states with the exception of New Hampshire and Iowa, the latter of which is considered a battleground state.

Tension between the White House and the DEA over marijuana rescheduling has been ongoing as some officials seem to sticking to the belief that cannabis has no medicinal benefits. This, despite the January release by the Department of Health and Human Services confirming that cannabis “has a currently accepted medical use in treatment in the United States” and a “potential for abuse less than the drugs or other substances in Schedules I and II."

The DEA Persists As Deadline Looms This collective effort comes ahead of the upcoming deadline to file comments urging the DEA to hold a hearing on the rescheduling proposal. "As DEA made clear in the Proposed Rule, additional data and rigorous scientific analysis is needed to determine whether marijuana is appropriately placed into Schedule III. Sifting through the competing claims about marijuana's pharmacological effects, potential for abuse, and implications for public safety are best done at a hearing," noted the agency.

Now Read: ‘The Banking Crisis For Cannabis Has Been Over’ For Several Years, Experts Discuss What’s Next?

The image was created using artificial intelligence.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.